| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | -0.14 | 3e-05 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.13 | 7e-05 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | 0.31 | 0.0001 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0004 |
| mRNA | 3-Cl-AHPC | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0006 |
| mRNA | CD-437 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0007 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0008 |
| mRNA | Teniposide | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0009 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.16 | 0.001 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |